Welcome to our dedicated page for Pao Group news (Ticker: PAOG), a resource for investors and traders seeking the latest updates and insights on Pao Group stock.
PAO Group, Inc. reports corporate developments for an OTC-traded holding company focused on legal-rights support and legal-practice referral activities. Recent company news includes leadership changes, rescinded material agreements, preferred-share capital-structure items, shareholder voting matters, governance updates, and operating and financial results.
Historical announcements also covered the company’s cannabis and CBD activities, including RX Branded CBD nutraceutical products, CBD intellectual property associated with a patented extraction method, and RespRx, a CBD formulation discussed for respiratory conditions such as COPD.
PAO Group, Inc. (OTC PINK: PAOG) is pursuing merger and acquisition opportunities to expand its product line and enhance revenue growth. The company has commenced production of its first line of CBD nutraceuticals and is on track to generate revenue this year. PAOG is leveraging its patented cannabis extraction method to develop CBD pharmaceuticals and nutraceuticals. The CBD nutraceuticals market was valued at $5.2 billion in 2020 and is projected to reach $16.4 billion by 2027. Distribution will occur through North American Cannabis Holdings, Inc. (OTC Pink: USMJ).
PAO Group, Inc. (OTC Pink: PAOG) has commenced production of its inaugural line of CBD nutraceuticals, anticipating revenue generation within 2021. The company leverages its patented cannabis extraction method (U.S. Patent No. 9,199,960) for developing these products. According to market estimates, the CBD nutraceuticals market was valued at $5.2 billion in 2020 and is projected to reach $16.4 billion by 2027. Distribution will be managed through North American Cannabis Holdings, Inc. (OTC Pink: USMJ). The company’s CBD initiatives also include a long-term pharmaceutical strategy stemming from a prior acquisition.
PAO Group, Inc. (OTC Pink: PAOG) plans to launch a CBD nutraceuticals line in 2021, aiming to capitalize on the booming CBD market, which is projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027. The company is leveraging its patented cannabis extraction method for product development. PAOG management expects mainstream CBD initiatives to validate and enhance visibility for their products. The CBD nutraceuticals will be part of a long-term pharmaceutical strategy stemming from an acquisition of intellectual property from Nouveau Life Pharmaceuticals.
PAO Group, Inc. (OTC Pink: PAOG) has partnered with Puration, Inc. (OTC Pink: PURA) to develop CBD pharmaceutical and nutraceuticals. Utilizing a patented cannabis extraction method, PAOG plans to launch a CBD nutraceuticals line expected to generate revenue in 2021. PURA is initiating the Farmersville Hemp Brand project, aiming to collectively market hemp products. A cannabis extraction lab will be built on PURA's 70-acre facility in Farmersville, Texas. The CBD nutraceuticals market is projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027.
PAO Group, Inc. (OTC Pink: PAOG) announced its plans to launch a CBD Nutraceuticals line expected to generate revenue in 2021. The CBD nutraceutical market, valued at $5.2 billion in 2020, is projected to reach $16.4 billion by 2027. PAOG will partner with Alkame Holdings for co-packing and North American Cannabis Holdings for distribution. Additionally, PAOG is developing RespRx, a pharmaceutical product for Chronic Obstructive Pulmonary Disorder (COPD). The company is also recovering 1.5 billion shares related to a previous acquisition.
PAO Group, Inc. (OTC Pink: PAOG) announced a CBD Nutraceuticals Business Development Update on June 24, 2021. The company aims to generate revenue from CBD Nutraceuticals this year, alongside its pharmaceutical projects. The CBD line includes products targeting anxiety and COPD, with anticipated market values reaching $18 billion and $16.4 billion respectively by 2025 and 2027. A new PhD in Pharmacological Sciences has joined the team to lead this initiative. PAOG plans collaboration with Alkame Holdings for production and North American Cannabis Holdings for distribution.
PAO Group (OTC Pink: PAOG) announced a CBD Nutraceuticals Business Development Update, set for release on June 23, 2021. The company aims to launch a CBD Nutraceuticals line expected to generate revenue within the year. Additionally, PAOG is working on a CBD pharmaceutical product, RespRx, targeting Chronic Obstructive Pulmonary Disorder, backed by a patented extraction method. Partnerships with Alkame Holdings, Inc. and North American Cannabis Holdings, Inc. are confirmed for copacking and distribution. The upcoming update will detail these roles and stock distribution to PURA shareholders.
PAO Group, Inc. (OTC Pink: PAOG) has confirmed that its CBD Nutraceuticals line is set to launch in 2021, aiming to generate revenue this year. The company will provide an update on this initiative on June 23rd, highlighting new developments that may enhance market opportunities. The CBD Nutraceuticals market, valued at $5.2 billion in 2020, is projected to reach $16.4 billion by 2027. Additionally, PAOG is developing RespRx, a CBD pharmaceutical for treating Chronic Obstructive Pulmonary Disorder, based on a patented extraction method.